Company Cash on Hand: Syros Pharmaceuticals (SYRS)

SYRS (Syros Pharmaceuticals, Inc.) - company brandmark

Geopolitical instability and the severance of scientific ties are hindering the innovative developments of Syros Pharmaceuticals (SYRS). The cash reserve trend captures this decline, where the value of 0.00 corresponds to the current metric. Syros Pharmaceuticals (SYRS) is currently struggling with a cash deficit and is reducing headcount following program failures. However, the success of future genetic research will ensure the monopoly sale of molecules with maximum operating leverage.

Syros Pharmaceuticals Inc. - SYRS Company Total Cash Amount (period 07/04/2022 - 03/29/2025)

Metric breakdowns and analytics for Syros Pharmaceuticals, Inc. (SYRS)

- company stock exchange capitalization indicators:
Comprehensive company analysis:SYRS Syros Pharmaceuticals
Brand item of syros.com

For the biotech startup Syros Pharmaceuticals (SYRS), liquidity levels determine the survival horizon prior to drug commercialization. This metric aggregates cash and cash equivalents, measuring the company's ability to fund R&D without external borrowing. By analyzing the company's cash dynamics, an investor assesses the risk of share dilution during secondary offerings. Amid intense competition with pharma behemoths, this reserve serves as a defense against acquisition. Sufficient capital guarantees the autonomy of developing unique therapy methods.

Competing companies

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Liquid Assets Mustang Bio MBIO|RNAZ: Company Cash Volume|Company Cash Position Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Company Cash Volume|bluebirdbio.com (BLUE) - Company Liquid Assets|Company Cash Volume IPA|Company Cash Volume Omega (OMGA)|Company Cash Funds Singular Genomics Systems Inc OMIC|Company Cash Volume Regulus RGLS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume